HKU Scholars Hub: Browsing DSpace

Browsing by Author Sukeepaisarnjaroen, W

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 5 to 15 of 15 < previous

	Title	Author(s)	Issue Date	Views
	Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Holmes, J Leerapun, A Tangkijvanich, P Strasser, S Jucov, A Gane, EJ Thi, EP Sevinsky, N Medvedeva, E Sharma, V Gray, K Antoniello, D Picchio, G Sims, K Eley, T	2022
	A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology	Yau, TCC Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Lencioni, R Camp, AC Cox, DS Kallender, H Ottesen, LH Poon, RTP	2012	88
	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research	Lim, HY Merle, P Weiss, KH Yau, TCC Ross, P Mazzaferro, V Blanc, JF Ma, YT Yen, CJ Kocsis, J Choo, SP Sukeepaisarnjaroen, W Gérolami, R Dufour, JF Gane, EJ Ryoo, BY Peck-Radosavljevic, M Dao, T Yeo, W Lamlertthon, W Thongsawat, S Teufel, M Roth, K Reis, D Childs, BH Krissel, H Llovet, JM	2018	50
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	74
	Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Strasser, S Tangkijvanich, P Holmes, J Leerapun, A Jucov, A Thi, EP Wattamwar, T Sofia, MJ Sevinsky, H Gray, K Antoniello, D Eley, T Picchio, G Sims, K Gane, E	2021	14
	Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/ 2a study Proceeding/Conference:Journal of Hepatology	Ma, H Lim, TH Leerapun, A Weltman, M Jia, JD Lim, YS Tangkijvanich, P Sukeepaisarnjaroen, W Bert, NL Ji, Y Li, D Zhang, Y Hamatake, R Strasser, S Li, C Ding, H Yoon, JH Nigel, S Anderson, D Yan, L Bertoletti, A Zhu, Q Yuen, RMF	2021	16
	Results of TRACER: a phase II randomized, double-blinded, multicenter Asian study investigating the combination of transcatheter arterial chemoembolization (TACE) and oral everolimus in localised unresectable hepatocellular carcinoma (HCC) Proceeding/Conference:Liver Cancer	Sukeepaisarnjaroen, W Lin, SM Lu, SN Paik, SW Tanwandee, T Lee, HC Chen, SC Yau, TCC Komolmit, P Ma, C Suryavanshi, M Xue, H Slader, C Poon, RTP	2016	64
	Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B Journal:Hepatology Communications	Yuen, MF Berliba, E Sukeepaisarnjaroen, W Ahn, SH Tanwandee, T Lim, YS Kim, YJ Poovorawan, K Tangkijvanich, P Schwabe, C Eley, T Brown, J Lee, ACH Thi, EP Paratala, B Mani, N Sofia, MJ Picchio, G Sims, KD Gane, EJ	4-Oct-2022
	Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects Proceeding/Conference:Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Ahn, SH Tanwandee, T Lim, Y-S Kim, YJ Poovorawan, K Tangkijvanich, P Chan, HLY Eley, T Brown, J Moore, C Lee, ACH Kim, J Thi, EP Mani, N Rijnbrand, R Cole, A Sofia, MJ Picchio, GR Sims, K Gane, EJ	2019	48
	The pharmacokinetic and safety profiles of RO7445482 SIRNA are similar between Asian and nonAsian healthy volunteers and chronic hepatitis B patients in a phase 1 Study Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Gane, EJ Guerreiro, N Buatois, S Kim, W Yoon, J-H Lim, TH Siever, W Thompson, A Sukeepaisarnjaroen, W Tangkijvanich, P Schwabe, C Brown, BD Triyatni, M Bo, QY Achneck, H Yuen, RMF	2021
	Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study Journal:JHEP Reports	Ma, HY Lim, TH Leerapun, A Wellman, M Jia, JD Lim, Y-S Tangkijvanich, P Sukeepaisarnjaroen, W Ji, Y Le Bert, N Li, D Zhang, Y Hamatake, R Tan, N Li, CM Strasser, SI Ding, HG Yoon, J-H Stace, NH Ahmed, T Anderson, DE Yan, L Bertoletti, A Zhu, Q Yuen, RMF	2021

Showing results 5 to 15 of 15 < previous